Filter By Category
Archives
Share on -
DROXINAVIR
Generic Name: DROXINAVIR
ABSTRACT -
Droxinavir is an investigational hydroxyethylurea HIV-1 protease inhibitor. Development was discontinued; it is included here as an API-style monograph entry rather than an approved product.
DOSAGE -
No approved dosage. In research settings, dosing followed protocol-specific investigational regimens.
SIDE EEFECTS -
- Gastrointestinal upset
- Fatigue or malaise
- Headache
- Laboratory abnormalities
- Potential antiviral-class drug tolerance issues
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Rash or urticaria
- Facial or throat swelling
- Bronchospasm or dyspnea
- Anaphylaxis (rare, emergency)
DRUG INTERACTIONS-
- Potential interaction with CYP-metabolized antiretrovirals
- Avoid unreviewed combinations with ritonavir/cobicistat boosters
- Additive toxicity with other investigational antivirals
PREAUTONS–
- Research-only/discontinued compound; do not use clinically outside authorized research
- Monitor liver chemistry and hematology in trial settings
- Assess HIV resistance patterns when studying protease inhibitors
WARNINGS –
- Not an approved medication
- Use only in accordance with validated investigational protocols
Share on -
. Developed by